Seres Therapeutics, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-10-26 reports Item 5.02 event concerning departure of directors/officers or compensatory arrangements as of 2026-10-22. The filing document itself contains no substantive detail of the specific personnel change, dollar amounts, or arrangement terms — only structural SEC filing metadata and XBRL taxonomy files are present in this submission.
Why this rating
No concrete facts disclosed (names, amounts, dates, terms absent). Routine 8-K filing with insufficient disclosure detail to assess materiality.
Extracted items
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.